Bangladesh Registration Dossier Checklist: From Agent Agreement to Annexure-3

1. Key takeaways

Bangladesh builds the registration dossier for Class B, Class C and Class D devices from nine components: a lawful agreement and power of attorney between manufacturer and local agent, the EC certificate and CE marking with an EC design examination certificate added for Class D, a country-of-origin CFS attested by the Bangladesh embassy, an original reference-country CFS for Class C and Class D, also attested, a recall history covering the past 2 years, a list of countries where the product is sold, physical packaging in the form of an empty box, label and IFU, 2 samples or a colour catalogue, and Annexure-3. Annexure-3 is the format table prescribed by DGDA and is mandatory, not optional.

The composition matters more than the length. Six of the nine items describe the commercial and legal relationship rather than the device, and several are declarations signed on the manufacturer’s letterhead that are read against each other rather than in isolation.

• Nine components for Class B, C and D, of which six are non-technical.
• Annexure-3 is the only item with an official DGDA format; the rest set content, not layout.
• 2 CFS documents for Class C and D, each separately attested, with the original required at final review.
• Recall history and country list signed on letterhead and drawn from one master data set.
• Packaging and samples are physical deliverables, so they carry transit time as well as preparation time.

2. Legal basis

The nine-item structure is the operational reading of the DGDA medical device registration guideline, supported in places by the conformity provisions of the same document. Where the source is a practical estimate rather than a quoted provision, the table says so, because that difference decides how much weight an item can carry.

Two features deserve emphasis. Only one item is defined by a mandated form, so the other eight are judged on content rather than layout. And attestation attaches to the CFS documents specifically: it is not a formality that can wait until the end, since any later change to the document voids it.

3. Expert insights

Insight 1: six of the nine items are non-technical, and that is where projects fail. The agreement, the two CFS documents, the recall history, the list of countries of sale, the packaging and Annexure-3 say nothing about design, biocompatibility or performance. Yet they are the items that most often delay a file, because they depend on signatures, notarisation, courier transit and the cooperation of parties outside the manufacturer’s direct control. The conclusion is uncomfortable for engineering-led organisations: the first barrier in Bangladesh is document governance, not research capability. A company that treats the dossier as a technical writing task and delegates the legal papers to an assistant usually finds the gap late, once the attestation chain has started on the wrong version of a certificate.

Insight 2: consistency across the list is more dangerous than the list itself. The recall history, the list of countries of sale and the CFS are all signed on letterhead, and each names the product, the model and the manufacturer. When those names differ by a word between documents, DGDA will question it directly, and the question is hard to answer because no single document is wrong. The cause is parallel drafting: one department writes the CFS application, another drafts the recall declaration, a third updates the label. Our rule is that all letterhead documents are generated from one master data set.

Insight 3: Annexure-3 is the one item that can be objectively wrong. The other eight describe what must be covered; Annexure-3 prescribes how it must be presented, which makes it the easiest item to fail on a technicality. We ask clients to obtain the current DGDA version from the local partner at the start of each project rather than reusing the form attached to an earlier submission, because the guideline itself is a living document, currently issued as Device Classification v 1.0. A superseded form is not a substantive defect, but it invites a resubmission that costs a full cycle.

Insight 4: the physical items set the critical path. An empty box, a printed label, an IFU and samples cannot be produced by a document team on short notice; they come from a production run and have to survive transit.

4. Practical recommendations

GRZAN runs every Bangladesh project against a nine-cell checklist. Each cell carries the document name, the issuing party, the signature requirement, the attestation requirement, the validity period, the owner and the completion date. The dossier is not bound until all nine cells are ticked, and the tick is given by the cell owner rather than the project lead, because the person who obtained the document knows whether it is complete. Before binding we compare the product name and manufacturer name word by word across the CFS, the recall history, the country list and the label; a single character of difference sends the document back for reissue.

• Assign an owner per cell. Legal papers, attestation, physical items and format compliance usually sit with different people.
• Freeze master data first. Agree the product name, model list, manufacturer name and address before any letterhead document is drafted.
• Start the attestation chain on day one. It is the only element whose duration is set entirely outside the project.
• Obtain the current Annexure-3 form per project. Confirm the version with the local partner in writing and keep the confirmation on file.
• Ship physical items early. Empty packaging and samples share a courier route with nothing else and should not wait for the paper file.

5. Verification checklist

• □ All nine components prepared and individually ticked by their owners
• □ Manufacturer and local agent agreement and power of attorney signed
• □ EC design examination certificate attached for Class D
• □ Country-of-origin CFS embassy attested; original reference-country CFS ready for Class C and D
• □ Recall history and list of countries of sale signed on letterhead, with consistent master data
• □ Physical packaging, meaning empty box, label and IFU, delivered to Bangladesh
• □ Annexure-3 completed on the current DGDA format
• □ Three internal reviews completed before the dossier is bound

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com